Appili Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

   GlobeNewswire MAY 1, 2025 7:34 AM EDT
   HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPin...
   READ ARTICLE

2. Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®(TM)

   GlobeNewswire APR 28, 2025 7:41 AM EDT
   New patents provide additional composition of matter and methods of use claims, strengthening the...
   READ ARTICLE

3. Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

   GlobeNewswire APR 2, 2025 8:17 AM EDT
   Event exploring the escalating threat of emerging infectious diseases Discussion covering...
   READ ARTICLE

4. Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

   Business Wire APR 2, 2025 8:15 AM EDT
   Event exploring the increasing risk of emerging infectious diseases Update on Appili tran...
   READ ARTICLE

5. Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

   Business Wire MAR 28, 2025 8:15 AM EDT
   The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chie...
   READ ARTICLE

6. Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

   Business Wire MAR 24, 2025 8:15 AM EDT
   Acquisition is key to Pearsanta’s mission of addressing cancer through early detection and...
   READ ARTICLE

7. Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

   GlobeNewswire MAR 18, 2025 7:22 AM EDT
   Four new funding proposals, totalling US$117.5 million, have been submitted for review Modi...
   READ ARTICLE

8. Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

   GlobeNewswire FEB 14, 2025 5:06 PM EST
   Received overwhelming shareholder support in favour of take-private transaction with Aditxt ...
   READ ARTICLE

9. Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

   Business Wire DEC 12, 2024 8:15 AM EST
   Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and S...
   READ ARTICLE

10. Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

    GlobeNewswire NOV 19, 2024 7:17 AM EST
    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
    READ ARTICLE